BNC, in collaboration with world leaders at University College London and Imperial College London, is developing innovative nanotechnology solution solutions to tackle social problems.

AquAffirm™

The World Health Organisation (WHO) has estimated that 130 million people globally drink water containing arsenic above safe levels, causing skin lesions, cancer and damage to the cognitive development of children. We are developing a unique arsenic sensor that uses technology modified from familiar glucose self-tests manufactured in the billions each year to create a step-change improvement in arsenic testing.

QELFA

image3344

According to a report published in 2012 by NHS Kidney Care, kidney disease costs the NHS over £1.4 billion per annum, more than breast, lung, colon and skin cancers combined. The NHS estimates that 1 million cases remain undiagnosed and thus untreated. These patients need to know they are at risk and take action so that this risk can be reduced. Using a unique proprietary technology capable of quantifying proteins in urine, BNC is delivering a quantitative test of kidney disease that can be used at near-patient settings.